Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Macular Edema Treatment Market Global Industry Size, Share, Outlook, and Forecast, 2018-2026

Author: Abhijit Ranjane
by Abhijit Ranjane
Posted: Apr 11, 2019
macular edema

Macular edema is the condition characterized by abnormal leakage and accumulation of fluid that forms blister in the layer of macula. The macula is an oval-shaped pigmented area near the center of retina. This blister causes the macula to swell and thicken that causes distortion of vision. Although macular edema has numerous causes, the most common cause is diabetes. Other causes include, age-related macular degeneration, replacement of lenses in treatment of cataract, chronic uveitis and intermediate uveitis, blockage of vein in the retina, and congenital diseases including retinitis pigmentosa and retinoschisis.

Get a PDF Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2494

Increasing number of pipeline studies is expected to drive the macular edema treatment market growth. For instance, in April 2018, University of California, Davis, in collaboration with IRIDEX Corporation, initiated phase 3 clinical trial for Micropulse Laser Treatment to evaluate micropulse for suppression of diabetic macular edema (pulse). The primary aim of the study is to determine whether the micropulse laser treatment in eyes with good visual acuity will improve or stabilize vision loss due to the complications of diabetic macular edema. The study is expected to be completed by December 2020.

Furthermore, increasing approval for new diabetic macular edema (DME) therapies is expected to propel growth for the macular edema treatment market. For instance, in March 2018, U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) 0.3 mg prefilled syringe (PFS) for diabetic macular edema and diabetic retinopathy. Lucentis 0.3 mg PFS is the first syringe prefilled with an anti-vascular endothelial growth factor (VEGF) agent. Moreover, in 2016 U.S.FDA approved Lucentis 0.5 mg PFS, which is intended for use in the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularisation (mCNV).

North America is expected to account for the largest market share in the macular edema treatment market, owing to increasing prevalence of diabetic macular edema in this region. For instance, according to American Journal of Managed Care (AJMC), in 2016, the prevalence rate of diabetic macular edema was 45.3% in North America.

Request for Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/2494

Moreover, in 2013, as per National Center for Biotechnology Information (NCBI), around 98 million individuals reported for diabetic retinopathy (DR) and 21 million individual reported for diabetic macular edema (DME) worldwide.

Furthermore, increasing product approvals for the treatment of macular edema is expected to boost growth of the macular edema treatment market in Europe. For instance, in 2015, the European Commission approved Eylea (aflibercept) for the treatment of patients with macular edema secondary to retinal vein occlusion. Bayer HealthCare and Regeneron collaborated to develop Eylea. Bayer HealthCare has exclusive marketing rights to the product outside the U.S.

Click To Continue Reading On Macular Edema Treatment Market

Key players operating in the macular edema treatment market include, Novartis International AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., Pfizer Inc. Bayer AG, Aerpio Therapeutics, Inc., Biomar Microbial Technologies, Antisense Therapeutics Limited, Coherus BioSciences, and Bausch & Lomb Incorporated.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

About the Author

Contact US: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel : +1-206-701-6702 Email: sales@coherentmarketinsights.com Website: https://www.coherentmarketinsights.com

Rate this Article
Leave a Comment
Author Thumbnail
Please or Join to add a comment.
Author: Abhijit Ranjane

Abhijit Ranjane

Flag of United States
United States

Member since: May 31, 2017
Total live articles: 375

Related Articles